Royalty Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	811.99	618.7	929.03	477.01	1,711	1,541
Short-Term Investments	-	-	-	-	24.42	581.87
Cash & Short-Term Investments	811.99	618.7	929.03	477.01	1,735	2,123
Cash Growth	28.50%	-33.40%	94.76%	-72.51%	-18.27%	6.57%
Accounts Receivable	31.47	29.32	26.96	22.41	36.6	68.31
Other Current Assets	921.11	880.08	846.16	774.78	783.14	686.98
Total Current Assets	1,765	1,528	1,802	1,274	2,555	2,878
Other Intangible Assets	-	-	-	-	-	5.67
Goodwill	923.54	924.63	-	-	-	-
Long-Term Investments	875.99	880.28	1,260	1,012	735.82	909.59
Other Long-Term Assets	16,256	16,288	15,161	14,095	13,523	13,722
Total Assets	19,820	19,621	18,223	16,382	16,813	17,516
Accounts Payable	35.57	19.4	13.37	15.17	7.91	5.62
Current Portion of Long-Term Debt	380	380	997.77	-	997.51	-
Other Current Liabilities	215.36	236.81	242.47	146.21	161.37	165.63
Total Current Liabilities	630.93	636.21	1,254	161.38	1,167	171.25
Long-Term Debt	8,582	8,571	6,615	6,135	6,119	7,096
Other Long-Term Liabilities	821.24	698.71	12.08	0.9	2.5	-
Total Long-Term Liabilities	9,403	9,270	6,627	6,136	6,121	7,096
Total Liabilities	10,034	9,906	7,880	6,298	7,288	7,267
Common Stock	0.05	0.04	0.05	0.05	0.04	0.04
Treasury Stock	-2.72	-2.61	-2.66	-2.63	-2.81	16.49
Additional Paid-in Capital	4,376	4,123	4,103	4,011	3,666	3,508
Accumulated Other Comprehensive Income	-	-	-	-	-	-2.72
Retained Earnings	2,459	2,356	2,846	2,518	1,965	2,255
Total Common Shareholders' Equity	6,833	6,477	6,947	6,526	5,628	5,777
Minority Interest	2,953	3,238	3,396	3,558	3,897	4,472
Shareholders' Equity	9,786	9,715	10,342	10,084	9,525	10,249
Total Liabilities & Equity	19,820	19,621	18,223	16,382	16,813	17,516
Total Debt	8,962	8,951	7,612	6,135	7,116	7,096
Net Cash (Debt)	-8,150	-8,332	-6,683	-5,658	-5,381	-4,973
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-14.62	-14.76	-11.25	-9.38	-12.29	-11.99
Book Value	6,833	6,477	6,947	6,526	5,628	5,777
Book Value Per Share	12.26	11.47	11.69	10.83	12.85	13.93
Tangible Book Value	5,909	5,552	6,947	6,526	5,628	5,771
Tangible Book Value Per Share	10.60	9.84	11.69	10.83	12.85	13.91

SEC Filings: 10-K · 10-Q